Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating safety and efficacy of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. The trial (firmMIND) is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Monjuvi (tafasitamab)
• Revlimid (lenalidomide)

Snippet

Sponsor: Incyte Corporation | Conditions: Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING